BioSpace News Archive

4C Medical Technologies, Inc., the creator of a new generation of therapies for structural heart disease, announced that its medical device therapy for mitral regurgitation, AltaValve™, was featured at Transcatheter Cardiovascular Therapeutics 2019, on Sept 25-29 in San Francisco, CA.

Sept. 30, 2019 07:00 UTC Tumor regressions and partial responses observed in subjects with ovarian, non-small cell lung and bladder cancer Treatment well-tolerated, with no related Grade 3-4 or immune-related adverse events DARTMOUTH, Nova Scotia--( BUSINESS WIRE )-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today presented preliminary results from its ongoing Phase 2 basket trial, evaluating DPX-Survivac in combination with Mer

Ascletis Pharma Inc., an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr. Lindi Tan, Chief Financial Officer, departs the Company

Octapharma announced that the European Medicines Agency has authorised an updated Summary of Product Characteristics for Nuwiq® that includes information on personalised prophylaxis in patients with haemophilia A.

Iksuda Therapeutics, a developer of next generation Antibody Drug Conjugates, announced the first data on its lead ADC, IKS01.

Two posters were presented during the European Society for Medical Oncology (ESMO) Congress 2019 on its RM-1929 photoimmunotherapy (PIT) treatment in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC)

WebMD Health Corp., an Internet Brands company and the leader in health information services for consumers, physicians, and other healthcare professionals, announced that it has entered into an agreement to acquire Aptus Health.

Final results from Phase 1 study of MTL-CEBPA in advanced liver cancer patients demonstrate clinical activity and attractive safety profile

Results from a study sponsored by Stemedica Cell Technologies, Inc., a global biotechnology company that uses allogeneic stem cells for ischemic conditions, form the basis for a peer-reviewed paper published in Stroke entitled “Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke.”

CStone Pharmaceuticals released pooled safety data from the Phase Ib study of the Company’s anti-PD-L1 antibody CS1001 in a poster presentation at the European Society of Medical Oncology 2019 Congress, demonstrating the promising safety and tolerability profile of CS1001.